August 31, 2009: Aurgalys-CLS publishes new analyst report on BioAlliance [EuroNext: BIO] on promising Acyclovir Lauriad data and company perpectives
août 31, 2009
Considering the following key points:
Acyclovir Lauriad® positive phase III results
Loramyc® sales increase for first half 2009
We observe that shares remain undervalued, thus we reiterate a BUY
recommendation
Download our BioAlliance Coverage here (available in english only)